MA52353A - Combinaison thérapeutique comprenant un tensioactif pulmonaire et un stéroïde pour la prophylaxie de la dbp - Google Patents

Combinaison thérapeutique comprenant un tensioactif pulmonaire et un stéroïde pour la prophylaxie de la dbp

Info

Publication number
MA52353A
MA52353A MA052353A MA52353A MA52353A MA 52353 A MA52353 A MA 52353A MA 052353 A MA052353 A MA 052353A MA 52353 A MA52353 A MA 52353A MA 52353 A MA52353 A MA 52353A
Authority
MA
Morocco
Prior art keywords
bpd
steroid
prophylaxis
combination including
therapeutic combination
Prior art date
Application number
MA052353A
Other languages
English (en)
Inventor
Noah Hillman
Alan Jobe
Matthew Kemp
Augusto Santos Schmidt
Original Assignee
Chiesi Farm Spa
Childrens Hospital Med Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa, Childrens Hospital Med Ct filed Critical Chiesi Farm Spa
Publication of MA52353A publication Critical patent/MA52353A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0082—Lung surfactant, artificial mucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA052353A 2018-04-23 2019-04-16 Combinaison thérapeutique comprenant un tensioactif pulmonaire et un stéroïde pour la prophylaxie de la dbp MA52353A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862661245P 2018-04-23 2018-04-23
US201862751830P 2018-10-29 2018-10-29

Publications (1)

Publication Number Publication Date
MA52353A true MA52353A (fr) 2021-04-28

Family

ID=66334409

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052353A MA52353A (fr) 2018-04-23 2019-04-16 Combinaison thérapeutique comprenant un tensioactif pulmonaire et un stéroïde pour la prophylaxie de la dbp

Country Status (9)

Country Link
US (2) US20190321452A1 (fr)
EP (1) EP3784212A1 (fr)
JP (1) JP7378425B2 (fr)
KR (1) KR102781186B1 (fr)
CN (1) CN112423733A (fr)
AU (1) AU2019260526B2 (fr)
MA (1) MA52353A (fr)
MX (1) MX2020011127A (fr)
WO (1) WO2019206731A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250172196A (ko) * 2024-05-31 2025-12-09 고려대학교 산학협력단 폐 계면활성제 및 항섬유화제를 포함하는 폐섬유증의 예방 또는 치료용 조성물 및 이의 제조방법

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260273A (en) 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US5164369A (en) 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
DE4418936A1 (de) 1994-05-31 1996-02-08 Byk Gulden Lomberg Chem Fab Polypeptid
US6019968A (en) * 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
IT1308180B1 (it) 1999-02-12 2001-12-07 Chiesi Farma Spa Peptidi sintetici aventi la capacita' di diminuire la tensionesuperficiale e loro impiego nella preparazione di un surfattante
WO2001085136A2 (fr) * 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Poudres a base de phospholipides permettant de distribuer un medicament
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
US7267121B2 (en) * 2004-04-20 2007-09-11 Aerogen, Inc. Aerosol delivery apparatus and method for pressure-assisted breathing systems
EP1674085A1 (fr) * 2004-12-22 2006-06-28 Universite Libre De Bruxelles Particules lipidiques solides comme charges pharmaceutiquement acceptables ou comme support pour inhalation
WO2006074296A1 (fr) * 2005-01-06 2006-07-13 Discovery Laboratories, Inc. Regime de traitement par tensioactifs pour le traitement prophylactique ou therapeutique de la dysplasie bronchopulmonaire
WO2007005672A2 (fr) * 2005-06-30 2007-01-11 The Scripps Research Institute Traitement et prevention de maladies et de situations respiratoires
US20070225233A1 (en) 2006-03-27 2007-09-27 Tsu-Fuh Yeh Reducing the risk of chronic lung disease in infants
EP2049554A4 (fr) 2006-07-20 2011-06-29 Univ Rochester Medical Ct Tensioactif pulmonaire synthetique et utilisation associée
EP1997502A1 (fr) 2007-06-01 2008-12-03 CHIESI FARMACEUTICI S.p.A. Agents tensioactifs reconstitués dotés de propriétés améliorées
US8048043B2 (en) 2007-06-08 2011-11-01 Chiesi Farmaceutici S. P. A. Method of administration of a pulmonary surfactant
CA2763402A1 (fr) * 2009-05-25 2010-12-02 Chiesi Farmaceutici S.P.A. Combinaison therapeutique comprenant un tensioactif pulmonaire et un steroide
US8399406B2 (en) 2009-06-05 2013-03-19 Chiesi Farmaceutici S.P.A. Reconstituted surfactant composition containing analogs of surfactant protein B (SP-B) and surfactant protein C (SP-C)
US9815869B2 (en) 2012-02-09 2017-11-14 University Of Rochester SP-B and SP-C peptides, synthetic lung surfactants, and use thereof
EA027030B1 (ru) 2012-04-23 2017-06-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ и система для введения легочного сурфактанта путем атомизации
RU2656185C2 (ru) * 2012-11-21 2018-05-31 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Реконструированные сурфактанты легких
CN105362220A (zh) * 2014-08-08 2016-03-02 深圳君圣泰生物技术有限公司 一种制剂及其制备方法、用途
EP3285645B1 (fr) * 2015-04-22 2020-08-12 Chiesi Farmaceutici S.p.A. Système pour une administration efficace, synchronisée avec la respiration, d'un médicament aux poumons
JP7777392B2 (ja) * 2016-12-22 2025-11-28 キエージ・フアルマチエウテイチ・エツセ・ピ・ア 進行性のｂｐｄの処置のための肺サーファクタント及びステロイドを含む処置的組み合わせ物

Also Published As

Publication number Publication date
US20210220445A1 (en) 2021-07-22
JP2021522263A (ja) 2021-08-30
EP3784212A1 (fr) 2021-03-03
CN112423733A (zh) 2021-02-26
KR20210005614A (ko) 2021-01-14
AU2019260526A1 (en) 2020-11-19
JP7378425B2 (ja) 2023-11-13
MX2020011127A (es) 2021-01-15
KR102781186B1 (ko) 2025-03-17
WO2019206731A1 (fr) 2019-10-31
US20190321452A1 (en) 2019-10-24
AU2019260526B2 (en) 2025-04-24

Similar Documents

Publication Publication Date Title
IL280972A (en) Devices for ventricular reshaping and heart valve reshaping
SG11202103377WA (en) Techniques for token proximity transactions
IL292690A (en) mrgprx2 antagonists for the treatment of inflammatory disorders
GB2571536B (en) Coherency manager
SI3802990T1 (sl) Obloga za spodnji ustroj tal
EP3807318A4 (fr) Constructions d'anticorps multi-spécifiques
PL3481846T3 (pl) 11-podstawione 24-hydroksysterole do stosowania w leczeniu stanów związanych z NMDA
IT201700100643A1 (it) Struttura di casseratura per l'esecuzione di getti per la realizzazione di solai
SG11202108627SA (en) Therapeutic antibody formulation
MA46621A (fr) Traitements combinés comprenant l'administration d'imidazopyrazinones
LT3897646T (lt) Macitentanas plaučių arterinei hipertenzijai gydyti
LT3687567T (lt) Anti-adrenomedulino rišiklis, skirtas panaudoti taikant ligos simptomų terapiją arba profilaktiką
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
PL3558376T3 (pl) Kombinacja terapeutyczna zawierająca surfaktant płucny i steroid do leczenia rozwijającej się BPD
HK1246394A1 (zh) 13+/17+bin1表达作为心脏病症的标记
EP3478274A4 (fr) Film à désintégration orale à action rapide pour l'administration d'une anesthésie locale
SG11202010138WA (en) Lopinavir and ritonavir for the treatment of cervix disorders
EP3525772A4 (fr) Formulations destinées à l'administration entérique d'agents thérapeutiques
MA52353A (fr) Combinaison thérapeutique comprenant un tensioactif pulmonaire et un stéroïde pour la prophylaxie de la dbp
HUE059211T2 (hu) Vakcinák vérzéses nyúlbetegség megelõzésére
PL4072532T3 (pl) Postać dawkowania do zastosowania w leczeniu lub zapobieganiu chorobie
EP3873808A4 (fr) Aéronef à configuration d'assise en angle
IL290902A (en) The compounds to identify beta-lactamases, and methods of use thereof
EP3897664A4 (fr) Fucosylation contrôlée d'anticorps
PL3839026T3 (pl) Sposób zwiększenia stabilności środków czyszczących